N. Ladisa

发表

Impact of Mutations Outside the V3 Region on Coreceptor Tropism Phenotypically Assessed in Patients Infected with HIV-1 Subtype B

L. Scudeller, G. Angarano, A. Saracino, 2011, Antimicrobial Agents and Chemotherapy.

Influence of Genotype 3 Hepatitis C Coinfection on Liver Enzyme Elevation in HIV-1-Positive Patients After Commencement of a New Highly Active Antiretroviral Regimen: Results From the EPOKA-MASTER Cohort

G. Sotgiu, L. Minoli, C. Torti, 2006, Journal of acquired immune deficiency syndromes.

Incidence and risk factors for liver enzyme elevation during antiretroviral therapy in HIV / HCV coinfected patients RUNNING HEAD : Hepatotoxicity in HIV / HCV coinfection

G. Filice, F. Mazzotta, G. Sotgiu, 2005 .

Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.

D. Francisci, L. Monno, R. Bucciardini, 2012, The Journal of antimicrobial chemotherapy.

Co‐receptor switch during HAART is independent of virological success

G. Angarano, A. Saracino, G. Punzi, 2009, Journal of medical virology.

Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART

L. Chatenoud, F. Castelli, A. Gori, 2015, PloS one.

A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.

C. Tinelli, A. Antinori, A. De Luca, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.

M. Milella, L. Scudeller, C. Fabrizio, 2017, International journal of antimicrobial agents.

Influence of HLA‐B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals

G. Angarano, A. Saracino, L. Monno, 2019, Journal of medical virology.

Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.

C. Tinelli, L. Minoli, C. Torti, 2005, The Journal of antimicrobial chemotherapy.

Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.

A. d’Arminio Monforte, V. Vullo, A. Antinori, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.

S. Di Giambenedetto, C. Torti, N. Manca, 2007, AIDS patient care and STDs.

Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.

R. Maserati, E. Ricci, G. Angarano, 2017, Atherosclerosis.

Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function

S. Di Giambenedetto, C. Torti, E. Quiros-Roldan, 2016, The open AIDS journal.

A. Antinori, A. Monforte, M. Trotta, 2002, Journal of acquired immune deficiency syndromes.

Cutaneous injection site reactions to long-term therapy with enfuvirtide.

R. Filotico, P. Maggi, G. Pastore, 2004, The Journal of antimicrobial chemotherapy.

Premature vascular lesions in HIV-positive patients: a clockwork bomb that will explode?

S. Ferraro, G. Angarano, A. Chirianni, 2002, AIDS.

Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.

A. Lazzarin, G. Guaraldi, C. Torti, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the “inflamm-aging” process

L. Scudeller, G. Angarano, A. Saracino, 2013, BMC Infectious Diseases.

Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.

N. Bartolomeo, M. Fasano, G. Angarano, 2015, The new microbiologica.

HCV-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?

M. Milella, L. Scudeller, C. Fabrizio, 2017 .

Desmopressin Treatment for a Case of Dengue Hemorrhagic Fever/ Dengue Shock Syndrome

S. Carbonara, G. Angarano, P. Maggi, 2001 .

No Evidence of Autoimmune Disorders in Antiretroviral-Experienced HIV-1-Infected Individuals after Long-Term Treatment with Raltegravir

V. Vullo, L. Palmisano, D. Francisci, 2013, Antiviral therapy.

Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration

V. Vullo, D. Francisci, M. Regazzi, 2010, The Annals of pharmacotherapy.

Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients.

G. Angarano, A. Saracino, P. Maggi, 2017, In vivo.

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

C. Tinelli, G. Filice, F. Mazzotta, 2005, BMC infectious diseases.

Chronic inflammation in a long-term cohort of HIV-infected patients according to the normalization of the CD4:CD8 ratio.

L. Scudeller, G. Angarano, A. Saracino, 2014, AIDS research and human retroviruses.

Does HIV-1 co-receptor tropism correlate with fibrosis progression in HIV/HCV co-infected patients?

L. Scudeller, G. Angarano, A. Saracino, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).

S. Leone, S. Lo Caputo, F. Mazzotta, 2015, International journal of epidemiology.

Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

E. Seminari, A. Lazzarin, A. Antinori, 2010, Antiviral therapy.

Original article Predicting the magnitude of short-term CD4 + T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

E. Seminari, A. Lazzarin, A. Antinori, 2010 .

Predictors of AIDS-Defining Events Among Advanced Naïve Patients After HAART

L. Minoli, C. Torti, G. Carosi, 2007, HIV clinical trials.

CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

R. Maserati, A. de Silvestri, A. Antinori, 2007, The Journal of antimicrobial chemotherapy.

Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals

G. Ippolito, M. Capobianchi, A. Monforte, 2005, Antiviral Therapy.

Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection.

C. Torti, G. Carosi, E. Quiros-Roldan, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Opportunistic parasitic infections of the intestinal tract in the era of highly active antiretroviral therapy: is the CD4(+) count so important?

S. Carbonara, G. Angarano, P. Maggi, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.

C. Tinelli, R. Maserati, A. Lazzarin, 2003, Journal of acquired immune deficiency syndromes.

Hepatitis C Infection Influence on Immune Recovery in HIV-Positive Patients on Successful HAART: The Role of Genotype 3

C. Tinelli, R. Maserati, E. Seminari, 2010 .

Selection of Antiretroviral Therapy Guided by Genotypic or Phenotypic Resistance Testing: An Open-Label, Randomized, Multicenter Study (PhenGen)

A. Antinori, F. Mazzotta, L. Scudeller, 2004, Journal of acquired immune deficiency syndromes.

Predictors of Clinical Progression among HIV-1–Positive Patients starting HAART with CD4+ T-cell Counts ≥200 cells/mm3

Carlo Torti, Massimo Di Pietro, Lorenzo Minoli, 2007, Antiviral therapy.

Influence of Hepatitis C Genotypes on Lipid Levels in HIV-Positive Patients during Highly Active Antiretroviral Therapy

C. Tinelli, R. Maserati, C. Torti, 2005, Antiviral therapy.

Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received

S. Di Giambenedetto, C. Torti, M. Fabbiani, 2012, AIDS Research and Therapy.

Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.

M. Prosperi, I. Frank, C. Torti, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Evaluation of glomerular filtration rate in HIV‐1‐infected patients before and after combined antiretroviral therapy exposure *

A. d’Arminio Monforte, A. De Luca, A. Gori, 2011, HIV medicine.

Induced first abortion rates before and after HIV diagnosis: results of an Italian self‐administered questionnaire survey carried out in 585 women living with HIV

A. d’Arminio Monforte, G. d’Ettorre, P. Cicconi, 2013, HIV medicine.

Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter Study

F. Donato, F. Castelli, A. Bandera, 2015, Journal of acquired immune deficiency syndromes.

Increasing Clinical Virulence in Two Decades of the Italian HIV Epidemic

Carlo Torti, Andrea De Luca, V. Müller, 2009, PLoS pathogens.

Difficulties in classifying a/g recombinants: methodological problems or genetic variability?

S. Lo Caputo, G. Angarano, A. Saracino, 2007, AIDS research and human retroviruses.

Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART

A. Lazzarin, O. Picconi, C. Mussini, 2010, PloS one.

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?

M. Milella, L. Scudeller, C. Fabrizio, 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study

A. Lazzarin, O. Picconi, C. Mussini, 2014, Retrovirology.

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study

A. Lazzarin, O. Picconi, C. Mussini, 2014, Retrovirology.

HIV‐1 DNA dynamics and variations in HIV‐1 DNA protease and reverse transcriptase sequences in multidrug‐resistant patients during successful raltegravir‐based therapy

D. Francisci, O. Cirioni, A. Cara, 2016, Journal of medical virology.

Increased immunoglobulin-secreting cells in the blood of patients with active idiopathic IgA nephropathy.

F. Schena, N. Ladisa, A. Pastore, 1986, Clinical nephrology.

PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection

R. Maserati, G. Nunnari, C. Sagnelli, 2017, PloS one.

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.

G. d’Ettorre, R. Bellagamba, G. Guaraldi, 2013, The Journal of antimicrobial chemotherapy.

Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

L. Chatenoud, F. Castelli, A. Gori, 2015, Journal of acquired immune deficiency syndromes.

Relationship Between Health-Related Quality of Life Measures and High HIV Viral Load in HIV-Infected Triple-Class-Experienced Patients

R. Bellagamba, G. Guaraldi, D. Francisci, 2014, HIV clinical trials.

Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study

F. Donato, A. Bandera, E. Raffetti, 2017, BMC Infectious Diseases.

Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study

F. Donato, A. Pan, M. Fabbiani, 2014, PloS one.

Prevalence of prolonged amenorrhea in HIV-infected women: results from the Italian DIDI study.

G. d’Ettorre, A. Monforte, P. Cicconi, 2012, Journal of acquired immune deficiency syndromes.

The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort

F. Castelli, A. Gori, C. Torti, 2016, BMC Public Health.

HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen.

L. Scudeller, C. Fabrizio, K. Falasca, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study

F. Donato, F. Castelli, A. Bandera, 2015, Journal of Translational Medicine.

Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.

G. d’Ettorre, D. Francisci, D. Segala, 2015, AIDS research and human retroviruses.

Evolution of Antiretroviral Prescription and Response over a Period of 8 years: an Italian Multicentre Observational Prospective Cohort Study

C. Tinelli, C. Torti, G. Carosi, 2008, Infection.

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment

M. Valsecchi, A. Gori, C. Torti, 2016, PloS one.

Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study

F. Donato, M. Fabbiani, E. Raffetti, 2015, BMC Public Health.

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

A. Riva, L. Galli, S. Di Giambenedetto, 2019, AIDS.

Reply to van der Pas et al

C. Torti, G. Carosi, E. Quiros-Roldan, 2011 .

An outbreak of HIV-1 BC recombinants in Southern Italy.

C. Balotta, G. Angarano, A. Saracino, 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The Efficiency of Sperm Washing in Removing Human Immunodeficiency Virus Type 1 Varies According to the Seminal Viral Load

J. R. Fiore, P. Greco, F. Lorusso, 2005 .

A greater prevalence of X4 viruses in HIV type 1 intravenous drug users reflects a "CD4+ effect".

L. Scudeller, G. Angarano, L. Monno, 2011, AIDS research and human retroviruses.

Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects.

S. Lo Caputo, L. Scudeller, G. Angarano, 2009, Antiviral research.

Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: Predictors of virological response and drug resistance evolution in a multi-cohort study

M. Prosperi, M. Zazzi, P. Cicconi, 2009, Infection.

Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort

M. Prosperi, A. Gori, A. Borghetti, 2017, BMC Infectious Diseases.

A multidrug-resistant (MDR) HIV type 1 infection in a homosexual man and identified source patient.

G. Angarano, A. Saracino, G. Punzi, 2007, AIDS research and human retroviruses.